Chronic Baseline Prostate Inflammation is Associated with Lower Tumor Grade in Men with Prostate Cancer on Repeat Biopsy: Results from the REDUCE Study

Authors:

Abstract
Purpose: We investigated whether baseline acute or chronic prostate inflammation among men with initial negative biopsies for prostate cancer (PCa) was associated with cancer-grade in 2-year repeat biopsies. Materials and Methods: Retrospective analyses were conducted of 889 men aged 50-75 years-old with negative baseline prostate biopsy and 2-year repeat biopsy positive for PCa in the Reduction by Dutasteride of PCa Events (REDUCE) study. Acute and chronic prostate inflammation and cancer-grade were determined by central pathology during the REDUCE study. The association of inflammation in baseline and 2-year repeat biopsy and PCa grade in 2-year repeat biopsy was evaluated with Student’s t test, chi-squared test and multivariable logistic regression. Results: Chronic, acute inflammation and both were detected in 533 (60%), 12 (1%) and 85 (10%) baseline biopsies, respectively. Presence of acute and chronic inflammation were significantly associated with each other (p <0.001). Both types of inflammation were unrelated to race, body mass index, prostate-specific antigen or digital rectal exam. At the 2-year biopsy, 621 (70%) tumors were low-grade (Gleason scores 2-6) and 268 (30%) were high-grade (Gleason scores 7-10). In uni- and multivariable analyses, men with baseline chronic inflammation had significantly less high-grade tumors (univariable odds ratio [OR]=0.64, 95% confidence interval [CI]=0.47–0.87, p=0.004; multivariable OR=0.68, 95% CI=0.50–0.93, p=0.016) than those without baseline chronic inflammation. Baseline acute inflammation was not associated with tumor grade (univariable OR=0.74, 95% CI=0.45–1.20, p=0.22; multivariable OR=0.78, 95% CI=0.48–1.29, p=0.34). Conclusions: Chronic inflammation in a negative biopsy was associated with lower PCa grade among men with cancer on follow-up 2-year biopsy.